results

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-‘749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with…

2 months ago

IOC Executive Board approves Olympic medal reallocations for Vancouver 2010 and Sochi 2014

19 September 2025 - The International Olympic Committee (IOC) Executive Board (EB) today took the decision to reallocate Olympic medals, diplomas and medallist…

2 months ago

Five Point Announces Expiration and Results of Cash Tender Offer for Any and All Outstanding 10.500% Initial Rate Senior Notes Due 2028

IRVINE, Calif.--(BUSINESS WIRE)--Five Point Holdings, LLC (“Five Point”) (NYSE: FPH) announced today that the cash tender offer (the “Offer”) commenced…

2 months ago

Algernon Announces Preferred Share Class Approved at Annual and Special Meeting

VANCOUVER, British Columbia, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB:…

2 months ago

No Difference in Transplant Outcomes Seen for Patients Unlikely to Find a Matched Unrelated Donor When a Donor Search Prognosis Strategy is Used

Published in the Journal of Clinical Oncology, results showed no difference in any outcomes, including overall survival, at two years…

2 months ago

Investing in Futures: Education Cannot Wait Reaches 14 Million Children in Crises Worldwide

New ECW Results Report highlights transformative education outcomes for children and adolescents in emergencies and protracted crises and calls for…

2 months ago

Novo Nordisks oral semaglutide 25 mg (Wegovy in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study

Oral semaglutide 25 mg (the once-daily pill formulation of Wegovy®) achieved significant weight loss, with one in three study participants…

2 months ago

Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease

SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering at Day 84 on the 9mg daily oral…

2 months ago

Green NCAP releases its latest round of 2025 results

WhatLatest Green NCAP results published online on new official website and via social media.WhenThursday 18 September - 11.00 a.m. CET.WhereGo…

2 months ago

ALCOR Scientific Transforms ESR Testing: Extends Blood Sample Stability from 4 to 28 Hours

Diagnostic Company's iSED Analyzers Deliver Seven-Fold Stability Increase to Improve Accuracy, Efficiency, and Patient Care SMITHFIELD, R.I., Sept. 16, 2025…

2 months ago